Streptococcus suis (S. suis) is an endemic cause of disease that results in significant economic losses to the pig industry throughout the world. The bacterium is transmitted from sows to piglets in the early days of life. Piglets develop disease post-weaning at between 4 and 10 weeks of age as the levels of maternal antibodies wane. Clinical signs include meningitis, arthritis, endocarditis and septicaemia leading to the death of many affected animals. The control of disease caused by S. suis currently requires the extensive use of antimicrobial agents, including penicillin. S. suis is also an important cause of zoonotic disease in humans. Therefore, the development of a safe and effective vaccine that protects piglets is an urgent unmet need.
"We reported previously proof-of-concept studies that showed our fusion protein vaccine prototype against Streptococcus suis was administered safely to pregnant sows and provided significant levels of protection to their piglets against an experimental challenge with S. suis at both four and seven weeks of age" explained
"There are approximately 10 million breeding sows in
For more information please contact:
Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73
E-mail: jonas.sohlman@intervacc.se
The information was submitted for publication, through the agency of the contact person set out above on
About
Contact information for Certified Adviser
E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10
https://news.cision.com/intervacc/r/u-s--patent-approval-for-intervacc-s-vaccine-against-infections-caused-by-streptococcus-suis,c3881051
https://mb.cision.com/Main/4632/3881051/2448627.pdf
https://news.cision.com/intervacc/i/a-new-generation-of-vaccines-within-animal-health,c3242194
(c) 2023 Cision. All rights reserved., source